WORKPACKAGE 6

Building and validation of a DCIS risk stratification model

In WP6 we will build a DCIS risk stratification model and develop a clinical assay based on molecular characteristics. We will use the data generated in WP1 (clinico-pathological data), WP2 (mutational data), WP3 (Immune infiltrate, heterogeneity), and WP4 (imaging) in a half as test and half as validation set.

The main lines of research are:

1. To assess the relative risk of a future event after a primary diagnosis of DCIS only. To this end we will both set up logistic regression models for the risk of a future in situ diagnosis as well as a future invasive event in the training dataset.
2. We will use these data to build a robust DCIS risk prediction model on the training data set. When a model with a good fit has been built it will be tested on the test dataset.
3. With the molecular markers identified, we will develop an easy to use, molecular-based assay which can be used in the clinic. To reach this aim, we will define the most discriminating molecular markers and bring them together in one focused assay.

Workpackage 6 is responsible for the respective project objectives to deliver a validated DCIS risk stratification model and to deliver a proof of concept diagnostic assay for prospective validation

Milestones

6.1 Collection and curation of all clinical and pathology data from DCIS retrospective cohorts
6.2 First analysis on RR/OR of combined clinic-pathological data
6.3 First model incorporating clinical, molecular and imaging data on training dataset
6.4 Validation of the model
6.5 Diagnostic assay developed

Three working groups support workpackage 6

WP lead

Dr Esther Lips

Associate staff scientist Molecular Pathology

The Netherlands Cancer Institute, Amsterdam, The Netherlands

Collaborators

Professor Lodewyk Wessels

The Netherlands Cancer Institute, Amsterdam, The Netherlands

 

Dr Marjanka Schmidt

The Netherlands Cancer Institute, Amsterdam, The Netherlands

 

Dr Eveline Bleiker

The Netherlands Cancer Institute, Amsterdam, The Netherlands

 

Dr Valesca Retel

The Netherlands Cancer Institute, Amsterdam, The Netherlands